Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nemolizumab for Pruritus Control in Cutaneous T-Cell Lymphoma: A Case Series.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

The dual burden of a rare cancer: psychosocial impact of disease symptoms and unmet care needs in cutaneous T-cell lymphoma.

Frontiers in psychology·2026
Same author

Dupilumab therapy in atopic dermatitis when cutaneous lymphoma is suspected: Consensus recommendations from the EORTC Cutaneous Lymphoma Tumour Group.

The Journal of allergy and clinical immunology·2026
Same author

Acquired Reactive Perforating Collagenosis following Cabozantinib - a case report.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Patient selection and treatment sequencing in RESMAIN - Author's reply.

The Lancet. Haematology·2026
Same author

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Cancers·2026

Related Experiment Video

Updated: Jul 15, 2026

Studying Chronic Exposure of Mice to Ultraviolet B Radiation
03:20

Studying Chronic Exposure of Mice to Ultraviolet B Radiation

Published on: August 19, 2025

Optimal combination with PUVA: rationale and clinical trial update.

Rudolf Stadler1

  • 1Department of Dermatology, Medical Centre Minden, Germany. hautklinik@klinikum-minden.de

Oncology (Williston Park, N.Y.)
|May 4, 2007
PubMed
Summary

Combination therapies, including psoralen plus ultraviolet A (PUVA) with interferon (IFN) alpha or bexarotene, show promise for managing cutaneous T-cell lymphoma (CTCL). Low-dose combinations may enhance safety and efficacy for early and advanced stages.

Related Experiment Videos

Last Updated: Jul 15, 2026

Studying Chronic Exposure of Mice to Ultraviolet B Radiation
03:20

Studying Chronic Exposure of Mice to Ultraviolet B Radiation

Published on: August 19, 2025

Area of Science:

  • Dermatology
  • Oncology
  • Immunology

Background:

  • Cutaneous T-cell lymphoma (CTCL) survival decreases with disease progression.
  • Current therapies aim to delay progression and minimize toxicity due to lack of curative treatments.
  • Monotherapy with agents like PUVA is insufficient for full disease control.

Purpose of the Study:

  • To explore the efficacy and tolerability of combination therapies for CTCL.
  • To investigate the potential of low-dose combination therapies for maintenance treatment.
  • To identify effective treatment strategies for both early and advanced CTCL stages.

Main Methods:

  • Review of existing studies on combination therapies for CTCL.
  • Analysis of treatment combinations including PUVA, interferon (IFN) alpha, bexarotene, and denileukin diftitox.
  • Evaluation of therapies for both early and advanced disease stages, including maintenance strategies.

Main Results:

  • Combination of PUVA with IFN alpha is effective and well-tolerated in early CTCL.
  • PUVA combined with bexarotene demonstrates good efficacy.
  • Bexarotene combined with IFN alpha or denileukin diftitox is effective in early stages.
  • Advanced CTCL may benefit from combinations like liposomal doxorubicin or extracorporeal photopheresis with bexarotene or IFN alpha.

Conclusions:

  • Combination therapy is essential for improving response rates in CTCL.
  • Low-dose combination therapies may offer improved safety and tolerability.
  • Effective treatment strategies exist for various stages of CTCL, including maintenance therapy.